Clinical Study
Radioactive Merano SPA Treatment for Allergic Rhinitis Therapy

Desiderio Passali,1 Giacomo Gabelli,1 Giulio Cesare Passali,2 Roberto Magnato,3 Stefan Platzgummer,4 Lorenzo Salerni,1 Salvatore Lo Cunsolo,5 Alexandra Joos,4 and Luisa Maria Bellussi1

1 ENT Department, University of Siena, Siena, Italy
2 ENT Department, Sacred Heart University, Roma, Italy
3 ENT Department, Tappeiner Hospital, Merano, Italy
4 Clinical Chemistry and Microbiology Laboratory, Tappeiner Hospital, Merano, Italy
5 Health Unit, Terme Merano, Merano, Italy

Correspondence should be addressed to Desiderio Passali; d.passali@virgilio.it

Received 24 May 2016; Accepted 16 August 2016

Academic Editor: Jan Betka

Copyright © 2016 Desiderio Passali et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Allergic rhinitis is a common nasal disorder with a high impact on quality of life, high social costs in therapies, and a natural development towards asthma. Its pathogenesis is based on an immune reaction against inhaled allergens. Sensitization to allergens is regulated by Th2 cells. When a person is exposed to allergens, to which he/she is sensitized, cross bonding occurs between IgE and allergens on mast cells, causing typical nasal symptoms within a few minutes. The symptoms are due to release of neuro- and vasoactive mediators, such as histamine, IL-4, leukotrienes, and prostaglandins [1]. At histological-cytological level, the normal status of nasal mucosa cells (ciliate cells, muciparous goblet cells, and basal cells) tends to change with the appearance of cells typical of inflammation, such as neutrophils, eosinophils, and mast cells.

Allergic rhinitis is defined by typical symptoms, such as nasal obstruction, abundance of clear/pale-coloured mucous secretion, itching, and sneezing. Treatment involves a combination of actions, such as limiting risk factors such as early allergen exposure, alleviating symptoms, and preventing sensitization. Pharmacological therapy is based on histamine antagonists, topical intranasal steroids, and specific immune

1. Introduction

Allergic rhinitis is a common chronic nasal disorder with a high impact on quality of life, high social costs in therapies, and a natural development towards asthma. Its pathogenesis is based on an immune reaction against inhaled allergens. Sensitization to allergens is regulated by Th2 cells. When a person is exposed to allergens, to which he/she is sensitized, cross bonding occurs between IgE and allergens on mast cells, causing typical nasal symptoms within a few minutes. The symptoms are due to release of neuro- and vasoactive mediators, such as histamine, IL-4, leukotrienes, and prostaglandins [1]. At histological-cytological level, the normal status of nasal mucosa cells (ciliate cells, muciparous goblet cells, and basal cells) tends to change with the appearance of cells typical of inflammation, such as neutrophils, eosinophils, and mast cells.

Allergic rhinitis is defined by typical symptoms, such as nasal obstruction, abundance of clear/pale-coloured mucous secretion, itching, and sneezing. Treatment involves a combination of actions, such as limiting risk factors such as early allergen exposure, alleviating symptoms, and preventing sensitization. Pharmacological therapy is based on histamine antagonists, topical intranasal steroids, and specific immune
therapy. Intranasal corticosteroids are currently the most widespread pharmacological therapy [2–4].

Thermal water treatment has traditionally been used as adjunctive treatment for chronic rhinitis, sinusitis, and bronchitis.

Several studies have found a correlation between therapy based on inhalation of mineral water with different physical and chemical characteristics (temperature, pressure, radioactivity, and the presence of specific ions or active chemical groups) and positive changes of subjective and objective parameters such as symptom and medication score, nasal resistance values, mucociliary clearance, and immunoglobulin concentration in nasal secretion and blood. They concluded that the mechanism of action of thermal treatment in chronic inflammation of the nose and paranasal sinuses is not limited to the action of cleansing, massage, and mucus dilution, but each type of thermal water has typical biological function related to its specific physical and chemical characteristics, thus implying specific indication in different pathologies [5–7].

The present study was conducted to assess the clinical efficacy of nasal inhalation of radioactive (481 Bq/l radon) oligomineral water hot vapours rich in fluorine from the Merano hot springs (Table 1) in allergy patients with nasal obstruction as main symptom. Primary outcome was the evaluation of the efficacy of the therapy by objective methods including bilateral flow and resistance measurement by active anterior rhinomanometry (AAR), mucociliary transport time (MCTt) determination, and nasal cytology. Secondary outcome was the subjective evaluation of symptoms by the Sino-Nasal Outcome Test (SNOT) questionnaire and the evaluation of treatment compliance in terms of side effects.

2. Methods

2.1. Patients. A comparative prospective study was performed with 90 allergic patients of both genders (age range 14–80 years) treated at Merano hot springs between March and October 2015. The main inclusion criterion was nasal obstruction, evaluated on the basis of medical history and a 10-Point Visual Analogue Scale, as well as a complete ENT examination. All patients enrolled in the study suffered from perennial allergic rhinitis, diagnosed by a prick test; among them 36 patients were monosensitized to D.pt. and 54 were positive to more than one allergen. They were randomly distributed in the two groups. No patient suffered from acetylsalicylic acid intolerance, asthma, or other comorbidities. Those with acute infectious rhinitis and nasal polyps at the enrolment time were excluded. Patients who had undergone pharmacological therapy with vasoconstrictors, topical corticosteroids, NSAIDs, systemic corticosteroids, or mucolytic agents in the previous two weeks were also excluded.

The study was conducted on a group (A) of 54 subjects treated with radioactive thermal oligomineral waters and a control group (B) of 36 subjects selected by the same criteria but treated topically with mometasone furoate nasal spray for 14 days, 2 puffs/nostril every morning, each puff consisting of 50 μg, equivalent to 200 μg of total dose per day for each patient. The patients were allocated in the two groups randomly (Table 2).

Group A underwent 14 days of inhalation therapy with radioactive thermal oligomineral water vapours at 38°C released 20 cm from the face in 8–10 μm micelles that do not penetrate beyond the upper airways. This treatment was followed by an aerosol of the same thermal water in 2–4 μm micelles that reach the lower airways. Each session lasted 10 minutes.

At the time of enrolment, personal data and medical history were recorded and a complete ENT examination was performed. Patients of both groups were assessed before and after treatment by compilation of the Sino-Nasal Outcome Test (SNOT score) questionnaire that investigates subjective levels of nasal obstruction, nasal itching, rhinorrhea, sneezing, and conjunctivitis [8, 9]; active anterior

### Table 1: Physical-chemical features of Merano thermal water.

| Parameters          | Results | Unit of measurement |
|---------------------|---------|---------------------|
| Atmospheric pressure| 981     | mbar                |
| Air temperature     | 22      | °C                  |
| Temperature at source| 23.4   | °C                  |
| Colour              | Colourless |                 |
| Odour               | Odourless |                |
| Savour              | Normal  |                     |
| Deposit             | Absent  |                     |
| Acidity (pH)        | 7.48    |                     |
| Conductivity (at source) | 77      | μS/cm               |
| Total hardness      | 3.2     | ′F                  |
| Alkalinity (as CO₃⁻) | 0       | mg/L                |
| Alkalinity (as HCO₃⁻) | 34      | mg/L                |
| Oxidability         | <0.5    | mg/L                |
| Ammonium ion (NH₄⁺) | <0.02   | mg/L                |
| Nitrites (NO₃⁻)     | <0.002  | mg/L                |
| Fluoride (F⁻)       | 1.3     | mg/L                |
| Chloride (Cl⁻)      | <1.0    | mg/L                |
| Nitrate (NO₂⁻)      | 0.6     | mg/L                |
| Sulphate (SO₄²⁻)    | 9       | mg/L                |
| Radon concentration | 246     | Bq/L                |

### Table 2: CONSORT diagram showing the allocation of patients during eligibility, enrolment, and follow-up phases.

| Randomization | Group A | Group B |
|---------------|---------|---------|
| Enrollment    | 54      | 36      |
| Drop-outs     | 8 patients did not attend the follow-up | None |
| Present at follow-up | 46 | 36 |
| Drop-outs     | 5 patients: resistance and mucociliary transport were impossible to assess | None |
| Completed a full valid follow-up | 41 | 36 |
Table 3: The table shows the statistical analysis of SNOT scores according to Wilcoxon test, expressed in absolute values. In the patients treated with thermal water, the mean switches from 29 points before treatment to 20 points after treatment. In those patients who underwent mometasone spray therapy, the mean decreases as well, from 38 to 22. \( p \) value is below 0.05 in both groups.

|                      | Before therapy | After therapy | \( p \)    |
|----------------------|----------------|---------------|------------|
| SNOT score of thermal water | 20/29/36       | 16/20/26      | 0.00000344 |
| SNOT score of mometasone    | 29/38/45       | 15/22/29      | 0.0000211  |

rhinomanometry (AAR) with bilateral flow and resistance monitoring and measurement of mucociliary clearance time were also performed in each patient. A rhinocytogram by nasal brushing/scraping of the inferior turbinate middle third was also taken.

All the patients in the study have given their informed consent to participate; the study protocol has been approved by Tappeiner Hospital, Merano, Italy.

2.2. Active Anterior Rhinomanometry. Nasal ventilatory function was evaluated by active anterior rhinomanometry according to validated criteria [10], using ATMOS Rhinomanometer 300. Three to five breaths were recorded at a fixed transnasal pressure of 150 Pa, with the mouth closed and the patient in seated position. Flow expressed in cc/sec and resistance expressed in Pascal were measured for the right and left nasal fossae and as overall value. Total resistance was calculated combining the resistances of the two nostrils according to the formula

\[
R_{\text{tot}} = \frac{R_{\text{left}} \times R_{\text{right}}}{R_{\text{left}} + R_{\text{right}}},
\]

2.3. Mucociliary Transport. Patients with nose and sinus pathology often have low mucociliary clearance [11], assessed as an increase in mucociliary transport time, expressed in minutes. In this study mucociliary transport time (MCTt) was calculated by placing a tracer powder (charcoal) on the head of the inferior turbinate. The path of the powder was followed by direct pharyngoscopy on the posterior wall of the pharynx. The charcoal powder is an inert nonsoluble tracer which is trapped in the gel layer of the mucus and is transported passively by the movement of the cilia [12]. Transport time was calculated as the average of the values obtained from the two nasal fossae.

2.4. Nasal Cytology. The rhinocytogram of a healthy person shows the cells that normally constitute the ciliated pseudostriatified epithelium: ciliated, muciparous, and basal cells. An increase in muciparous goblet cells and the presence of other types of cell, such as neutroph granulocytes, eosinophils, mast cells, or fungal hyphae and bacteria, provide an indication of nasal inflammation.

In the present study, the cytological sample was obtained by bilaterally brushing or scraping the middle third of the inferior turbinate. The harvested nasal cells were placed on a microscope slide and fixed immediately for cytopathological examination. After the May-Grunwald-Giemsa staining, the slides were examined under light microscopy: examination was carried out at ×100 magnification and 6 representative microscopic fields for each slide were examined.

2.5. Statistical Analysis. The study was designed to compare objective clinical criteria before and after treatment. The comparison was between group A consisting of 54 subjects treated with radioactive oligomineral thermal waters and group B consisting of 36 controls selected by the same criteria but treated topically with mometasone nasal spray for 14 days.

Flow and resistance values measured by active anterior rhinomanometry (AAR) and mucociliary transport time in minutes were divided into quartiles and their statistical significance was tested by the Wilcoxon test. Differences in cell populations detected by cytological analysis were expressed as mean number of cells found on each slide for each group of patients. The statistical significance was evaluated by the Wilcoxon test.

3. Results

Analysis of the results was conducted including only those subjects who completed the treatment and underwent enrolment and follow-up examination.

The SNOT score results decreased both in the group of patients who underwent thermal water therapy, from a mean of 29 points to 20 points, and in the group following mometasone therapy, from 38 to 22 points (Table 3 and Figure 1).

With regard to combined flow and resistance data (right and left nasal fossa), the thermal treatment group showed an increase in flow from a mean of 482 cc/s to 528 cc/s (+9.54%), whereas the group treated with mometasone showed an increase in flow from a mean of 470 cc/s to 492 cc/s (+4.68%) \( (p = 0.049) \).
Table 4: The table shows the results of statistical analysis according to Wilcoxon test, comparing the flow and resistance data got by active anterior rhinomanometry and the mucociliary time data, before and after thermal water therapy and mometasone nasal spray. In 46 cases encompassed by the study with thermal water therapy (w), we notice increase of combined flow (right + left) after thermal therapy, switching the mean from 482 cc/s before therapy to 528 cc/s after therapy (\(p = 0.168\)). The data refers to first quartile/mean/third quartile. After the therapy with mometasone nasal spray (m) (36 cases), an increase of flow (\(dx + sx\)) is noticed, switching the mean from 470 cc/s to 492 cc/s with \(p = 0.049\); the value of resistance, from 0.34, reduces to 0.26 Pa/cc with \(p = 0.093\). Mucociliary transport time decreases from 14 minutes to 13 with \(p = 0.00324\). The data refers to first quartile/mean/third quartile.

|                      | Before therapy | After therapy | \(p\)   |
|----------------------|----------------|---------------|---------|
| Flow (cc/s)          |                |               |         |
| Left (\(N = 46\)) w | 176/234/340    | 180/250/436   | 0.041   |
| Left (\(N = 36\)) m | 110/188/232    | 190/268/460   | 0.078   |
| Right (\(N = 46\)) w| 152/246/332    | 116/234/376   | 0.796   |
| Right (\(N = 36\)) m| 114/220/388    | 228/240/296   | 0.495   |
| Total (\(N = 46\)) w| 340/482/676    | 328/528/756   | 0.168   |
| Total (\(N = 36\)) m| 352/470/604    | 474/492/602   | 0.049   |
| Resistance (Pa/cc)   |                |               |         |
| Left (\(N = 41\)) w | 0.385/0.55/0.765| 0.335/0.46/0.815| 0.334   |
| Left (\(N = 36\)) m | 0.56/0.68/0.965 | 0.32/0.5/0.77  | 0.142   |
| Right (\(N = 41\)) w| 0.3975/0.55/0.8625| 0.3675/0.48/0.8025| 0.721   |
| Right (\(N = 36\)) m| 0.34/0.62/0.87  | 0.40/0.55/0.65 | 0.151   |
| Total (\(N = 41\)) w| 0.1975/0.25/0.405| 0.17/0.23/0.44 | 0.76    |
| Total (\(N = 36\)) m| 0.20/0.34/0.42  | 0.22/0.26/0.29 | 0.093   |
| Mucociliary transport (minutes) | | | |
| Thermal water (\(N = 41\)) | 12,375/13/14 | 11/12/25 | 0.000001208|
| Mometasone (\(N = 36\)) | 13,0/14,0/15,0 | 12,0/13,0/14,0 | 0.00324 |

Table 5: The table compares the results of cytological analysis according to Wilcoxon test in the patients who followed thermal water therapy and mometasone nasal spray. Regarding the thermal water therapy group, the sample of patients allowed getting significant data about ciliated cells, goblet cells, neutrophils, and eosinophils. The mean of each type of cell per microscopic field is shown, considering the whole group of 46 patients. Ciliated cells increased, from a mean of 30 to 33.47; goblet cells (considering also the standard deviation, here not reported) remain stable (from 28 to 29.5); neutrophils almost halve (\(p = 0.187\)); eosinophils decrease from a mean of 0.26 to 0.065 (\(p = 0.08\))). Regarding the cytological exam of 36 patients treated by mometasone there were significant outcomes concerning ciliated cells and goblet cells. In particular, the mean of ciliated cells per field increased from 25.71 to 30; the mean of goblet cells decreased from 30 to 27.14.

|                      | Before therapy | After therapy | \(p\)   |
|----------------------|----------------|---------------|---------|
| Ciliated cells       |                |               |         |
| Th. water            | 30             | 25,71         |         |
| Mom.                 | 33.47          | 30            | 0.421   |
| Th. water            | 0.26           | 0.071         | 0.08    |
| Eosinophils          | 8,13           | 6,28          | 0.187   |
| Basophiles           | 0,021          | 0             | 1       |
| Mast cells           | 0              | 0             | 1       |
| Macrophages          | 0              | 0.21          | 1       |
| Lymphocytes          | 0              | 0             | 1       |
| Bacteria             | 0              | 0             | 1       |
| Fungi                | 0              | 0.14          | 1       |

Resistance decreased from a mean of 0.25 Pa/cc to 0.23 Pa/cc (\(-8.0\%\)) (\(p = 0.76\)) in the thermal treated group and from a mean of 0.34 Pa/cc to 0.26 Pa/cc (\(-23.5\%\)) (\(p = 0.093\)) in the control group. Mucociliary transport time improved significantly in the thermal treated group (\(p = 0.0000012\)) and in the mometasone treated group (\(p = 0.00324\)). Mean MCT time fell from 13 to 12 min in group A and from 14 to 13 min in controls (Table 4 and Figures 2, 3, and 4).

With regard to cytological analysis, an increase in ciliated cells from a mean of 30 to 33.47 per microscope field was recorded in thermal treated patients (46 cases) as well as a decrease in neutrophils from a mean of 8 to 4 per field and in eosinophils from 0.26 to 0.065 per field. Patients treated with mometasone showed an increase in ciliated cells from 25.7 to 30 per field and a decrease in muciparous goblet cells from 30 to 27.4 per field (Table 5 and Figures 5, 6, 7, 8, 9, 10, 11, and 12).

No difference was recorded in the outcomes between mono- and polysensitized patients.

The cycle of thermal inhalations was well tolerated and no side effects were reported by patients. Among patients treated with mometasone furoate nasal spray, two reported annoying pruritus and three complained of moderate epistaxis.
4. Discussion

Nasal irrigation using saline solutions has been recommended as complementary treatment of AR in several studies and international guidelines [13–18]. Its efficacy has been clearly established in a systematic review with meta-analysis [19]: ten prospective randomized controlled studies with a total of 400 patients were considered in the review. Meta-analysis was performed with regard to the parameters "nasal symptom score," "medicine consumption," "mucociliary clearance time," and "quality of life" in terms of the
respective absolute improvement in comparison between the beginning and the end of the study. The review showed that nasal irrigation with saline solution in AR results in the improvement of symptoms, quality of life, and MCT; thus it is effective on subjective and objective parameters and in children, adolescents, and adults including pregnant women. However the heterogeneity of the analyzed studies regarding type, amount, and timing of nasal irrigation and the use of different saline solutions (isotonic, hypertonic) asks for additional studies to be performed in the future to clarify the questions as to the optimal salt concentration and mode of application.

A systematic review with meta-analysis [20] on the effectiveness of thermal water treatment in upper respiratory tract diseases has been recently published. 13 studies were included in the meta-analysis, 7 of which were randomized and controlled. Isotonic sodium chloride solution was used for control groups and drinking water or distilled water for the placebo groups. Definitively the review states that thermal waters have not only a function of cleansing, massage, and dilution, but fully therapeutic function as well demonstrating clear advantages on objective parameters, such as MCT, nasal flow, nasal resistance, and IgE concentration, over isotonic saline solution and placebo.

The effect of antihistamine medications on ciliary function and nasal patency has been tested in literature as well. Loratadine, levocabastine, and xylometazoline have not showed an enhancement of mucociliary function in terms of mucociliary transport time reduction and ciliary beat frequency [21–23]. Azelastine seems to cause a reduction of ciliary activity [24].

Nasal airways resistance and mucous secretions are reduced by antihistamine therapy [25,26].

At present, there is a lack of studies which compare the traditional therapies with thermal therapy, following objective parameters.

Our study showed that inhalation treatment with radioactive hydrofluoric thermal water for two weeks produces an objective clinical and cytological improvement in allergic patients, similar to that obtained with mometasone furoate nasal spray. Specifically, inhalation of thermal waters brought about an improvement in bilateral nasal flow and hence a decrease in resistance to air flow. Mucociliary function was also modified by thermal therapy; clearance time decreased similar to the decrease obtained with mometasone therapy.

Cytological examination showed effects of thermal therapy over different cell populations. In particular, it proved effective in restoring correct mucociliary function, since it led to an increase in ciliated cells and a stabilisation of goblet cells parallel to the mucociliary clearance improvement. Thermal
therapy also contributed to alleviation of chronic inflammation, since the neutrophils and eosinophils population decreased after treatment.

The SNOT score decreased both after water thermal therapy and after mometason, showing the benefits of thermal treatment in the perception of allergic rhinitis symptoms.

Competing Interests

The authors declare that there is no conflict of interests regarding the publication of this paper. In particular, dr. Salvatore Lo Cunsolo, being the Chairman of Health Unit, does not have any conflict of interests with Therme Administration.

References

[1] L. M. Wheatley and A. Togias, "Allergic rhinitis," The New England Journal of Medicine, vol. 372, no. 5, pp. 456–463, 2015.
[2] P. Giavina-Bianchi, R. Agondi, R. Stelmach, A. Cukier, and J. Kilić, "Fluticasone furoate nose spray in the treatment of allergic rhinitis," Therapeutics and Clinical Risk Management, vol. 4, no. 2, pp. 465–472, 2008.
[3] G. K. Scadding, "Optimal management of allergic rhinitis," Archives of Disease in Childhood, vol. 100, no. 6, pp. 576–582, 2015.
[4] G. Solelhac and D. Charpin, "Management of allergic rhinitis," F1000Prime Report, vol. 6, article 94, 2014.
[5] G. Ottaviano, G. Marioni, C. Staffieri et al., "Effects of sulfurous, salty, bromic, iodic thermal water nasal irrigations in nonallergic chronic rhinosinusitis: a prospective, randomized, double-blind, clinical, and cytological study," American Journal of Otolaryngology—Head and Neck Medicine and Surgery, vol. 32, no. 3, pp. 235–239, 2011.
[6] D. Passali, E. De Corso, S. Platzgummer et al., "SPA therapy of upper respiratory tract inflammations," European Journal of Oto-Rhino-Laryngology, vol. 270, no. 2, pp. 565–570, 2013.
[7] A. Staffieri and A. Abramo, "Sulphurous-arsenical-ferruginous (thermal) water inhalations reduce nasal respiratory resistance and improve mucociliary clearance in patients with chronic sinonasal disease: preliminary outcomes," Acta Oto-Laryngologica, vol. 127, no. 6, pp. 613–617, 2007.
[8] A. S. De Conde, J. C. Mace, T. Bodner et al., "SNOT-22 quality of life domains differentially predict treatment modality selection in chronic rhinosinusitis," International Forum of Allergy and Rhinology, vol. 4, no. 12, pp. 972–979, 2014.
[9] A. S. Deconde, J. C. Mace, J. A. Alt, L. Rudmik, Z. M. Soler, and T. L. Smith, "Longitudinal improvement and stability of the SNOT-22 survey in the evaluation of surgical management for chronic rhinosinusitis," International Forum of Allergy and Rhinology, vol. 5, no. 3, pp. 233–239, 2015.
[10] R. Eccles, "A guide to practical aspects of measurement of human nasal airflow by rhinomanometry," Rhinology, vol. 49, no. 1, pp. 2–10, 2011.
[11] N. A. Cohen, "Sinonasal mucociliary clearance in health and disease," The Annals of Otolaryngology, Rhinology & Laryngology. Supplement, vol. 196, pp. 20–26, 2006.
[12] D. Passali, C. Mezzedimi, G. C. Passali, D. Nuti, and L. Bellussi, "The role of rhinomanometry, acoustic rhinometry, and mucociliary transport time in the assessment of nasal patency," Ear, Nose & Throat Journal, vol. 79, no. 5, pp. 397–400, 2000.
[13] J. L. Brozek, J. Bousquet, C. E. Baena-Cagnani et al., "Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines 2010 Revision," Journal of Allergy and Clinical Immunology, vol. 3, pp. 466–476, 2010.
[14] W. Garavello, M. Romagnoli, L. Sordo, R. M. Gaini, C. Di Berardino, and A. Angrisano, "Hypersaline nasal irrigation in children with symptomatic seasonal allergic rhinitis: a randomized study," Pediatric Allergy and Immunology, vol. 14, no. 2, pp. 140–143, 2003.
[15] W. Garavello, F. Di Berardino, M. Romagnoli, G. Sambataro, and R. M. Gaini, "Nasal rinsing with hypertonic solution: an adjunctive treatment for pediatric seasonal allergic rhinoconjunctivitis," International Archives of Allergy and Immunology, vol. 137, no. 4, pp. 310–314, 2005.
[16] W. Garavello, E. Somigliana, B. Acaia, L. Gaini, L. Pignataro, and R. M. Gaini, "Nasal lavage in pregnant women with seasonal allergic rhinitis: A Randomized Study," International Archives of Allergy and Immunology, vol. 151, no. 2, pp. 137–141, 2010.
[17] H. Li, Q. Sha, K. Zuo et al., "Nasal saline irrigation facilitates control of allergic rhinitis by topical steroid in children," ORL, vol. 71, no. 1, pp. 50–55, 2008.
[18] A. Rogkakou, L. Guerra, P. Massacane et al., "Effects on symptoms and quality of life of hypertonic saline nasal spray added to antihistamine in persistent allergic rhinitis—a randomized controlled study," European Annals of Allergy and Clinical Immunology, vol. 37, no. 9, pp. 353–356, 2005.
[19] K. E. Hermelingmeier, R. K. Weber, M. Hellmich, C. P. Heubach, and R. Mösges, "Nasal irrigation as an adjunctive treatment in allergic rhinitis: a systematic review and meta-analysis," American Journal of Rhinology and Allergy, vol. 26, no. 5, pp. e119–e125, 2012.
[20] S. Keller, V. König, and R. Mösges, "Thermal water applications in the treatment of upper respiratory tract diseases: a systematic review and meta-analysis," Journal of Allergy, vol. 2014, Article ID 943824, 17 pages, 2014.
[21] L. M. Lee and B. S. Gendeh, "Pre and post treatment mucociliary function in allergic rhinitis in three different treatment modalities," Medical Journal of Malaysia, vol. 58, no. 1, pp. 17–20, 2003.
[22] F. W. H. M. Merkus and M. T. L. W. Schüsler-van Hees, "Influence of levocabastine suspension on ciliary beat frequency and mucociliary clearance," Allergy, vol. 47, no. 3, pp. 230–233, 1992.
[23] W. M. Boek, K. Graamans, H. Natzijl, P. P. van Rijk, and E. H. Huizing, "Nasal mucociliary transport: new evidence for a key role of ciliary beat frequency," The Laryngoscope, vol. 112, no. 3, pp. 570–573, 2002.
[24] J. Alberty and W. Stoll, "The effect of antiallergic intranasal formulations on ciliary beat frequency of human nasal epithelium in vitro," Allergy, vol. 53, no. 10, pp. 986–989, 1998.
[25] E. A. McFadden, A. Gungor, B. Ng, B. Mamiokoglu, R. Moinuddin, and J. Corey, "Loratidine/pseudoephedrine for nasal symptoms in seasonal allergic rhinitis: A Double-Blind, Placebo-Controlled Study," Ear, Nose and Throat Journal, vol. 79, no. 4, pp. 254–260, 2000.
[26] F. Horak, J. Toth, B. Marks et al., "Efficacy and safety relative to placebo of an oral formulation of cetirizine and sustained-release pseudoephedrine in the management of nasal congestion," Allergy, vol. 53, no. 9, pp. 849–856, 1998.